Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (20148)	3/27/1999 6:12:00 PM
From: tommysdad	Respond to of 23519

A nice piece of work, but probably not commercially viable. Lots of copper to get rid of (expensive -- copper is not an environmentally benign metal), and top that off with a bunch of (toxic!) trialkyltin waste. An extremely expensive method of preparation. The FDA also does not like processes that use tin, particularly near the end of the synthesis, where contamination is a real concern. This patent is unlikely to have any bearing on anyone who actually wants to make these compounds for commercial use.